Interleukin Genetics has expanded its Waltham, Mass., facilities, and has hired four new managers: Taha Keilani will become medical director; Christopher Palatucci will become senior director of business development and licensing; Paul Voegelin will become director of operations and planning; and Gary Breton will become DNA laboratory manager (see SNIPPETS, page 7, for details about the expansion).
The National Cancer Institute has hired two new deputy directors, the institute said in a statement this week: Karen Antman will officially assume her post on April 18 and will offer strategic scientific direction as deputy director for Translational and Clinical Science; and Mark Clanton, the deputy director for Cancer Care Delivery Systems, will oversee health care system design. Additionally, NCI has named James Doroshow as director for its Division of Cancer Treatment and Diagnosis; he is slated to lead the NCI Clinical Trials Working Group.
Specifically, Antman will direct a national research program that includes the NCI-designated Cancer Centers Program and the disease-oriented Specialized Programs of Research Excellence.
She comes to NCI from the Columbia University Comprehensive Cancer Center, where she was director of and chief of the Division of Medical Oncology.
Clanton, former president-elect of the American Cancer Society, will coordinate health economics, clinical effectiveness, and cancer patient outcomes research to “maximize NCI’s ability to influence the delivery of care to people with cancer,” NCI said in a statement.
Doroshow comes to NCI from City of Hope in Los Angeles, where he was chairman of the Department of Medical Oncology and Therapeutics Research and associate director for clinical research at the City of Hope Comprehensive Cancer Center.
His responsibilities at NCI include ensuring that the institute’s Clinical Trials Working Group develops “new paradigms to re-direct the clinical trials infrastructure from the traditional single-agent safety, efficacy, and comparison process to one of multiple interventions using innovative study designs, end-point determinations, enhanced public-private partnerships, and a shared bioinformatics platform,” NCI said.
J. Mark Lievonen has joined the board of directors of Oncolytics, the Calgary, Canada-based company said in a statement this week. He is president of Aventis Pasteur, and since 2003, he has been a director of the Ontario Genomics Institute board. Lievonen holds an MBA and a bachelor’s degree in business administration from York University in Toronto.